Notice of Intent to Sole Source Gen-Probe - Fusion SARS-CoV-2

The Department of the Army Medical Command published a Special Notice of Intent to Sole Source Gen-Probe for COVID-19 testing kits and services. The justification document attached to the Notice seeks approval for other than full and open competition under FAR 6.302-1 as Gen-Probe is the only supplier licensed by Hologic to sell and service its COVID-19 testing products that are compatible with the Army's existing Hologic Panther Fusion systems.

The Special Notice aims to procure Panther Fusion SARS-CoV-2 assays, Aptima SARS-CoV-2 assays, and multiplex test kits from Gen-Probe to conduct COVID-19 testing at multiple Army medical treatment facilities through May 2021, with an anticipated one to three-year ordering period valued between $XX million initially and $XX million total. Interested contractors must review the justification document for eligibility criteria as the Special Notice seeks approval to award sole source to Gen-Probe due to Hologic's licensing restrictions preventing other suppliers from meeting the Army's requirements to use FDA-authorized tests that integrate with its Panther Fusion systems.